Pharmafile Logo

Digital Therapeutics Landscape in Europe

September 3, 2020 |  

OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

Digital Therapeutics Landscape in Europe: The Case of Germany and the UK

The COVID-19 virus crisis has opened immense windows of opportunity in healthcare around the globe. One of the greatest opportunities is in digital health, and in particular, digital therapeutics (DTx). The need for continued medical care combined with social distancing has led to a spike in use of digital health tools worldwide.1 As the interest in and use of digital health has grown during this period, we anticipate that investments in digital health tools will continue to accelerate after the COVID-19 pandemic. When the COVID-19 outbreak started, millions of Chinese people turned to online doctors and online health tools1 to find the needed support for their health. While these developments could create new risks for privacy and data protection, they also represent an unprecedented opportunity to integrate industry 4.0 in healthcare for the benefit of patients.

HIGHLIGHTS INCLUDE:
  • Opportunities and threats of digital therapeutics after COVID-19
  • Digital therapeutics landscape in the European Union
  • Review and comparison of the German and UK therapeutics landscape
  • Develop game-changing insights and competitive advantage on both a global and local scalepi

Pink divider

Download the white paper and learn how it’s happening now!

Download the Paper- PMLiVE

  1. https://www.cnbc.com/2020/03/26/investments-in-digital-health-care-could-accelerate-after-coronavirus-credit-suisse-says.html

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Rare Disease Day 2021

To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to...

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health

If the heart of the medical affairs industry is ultimately improving patient outcomes, internal training is the regenerative liver. Med affairs professionals need to regularly update their scientific knowledge and...

What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

How fantastic is it to see that the National Organisation for Rare Disorders (NORD) has followed up on a survey undertaken in the late 80’s to pressure test progress and identify...

OPEN Health Group Appoints New Leadership

OPEN Health Group today announced that Rob Barker has been appointed Chief Executive Officer. Rob succeeds outgoing CEO and Co-Founder, David Rowley, who is stepping down after 10 years. A...

OPEN VIE and Pharmerit Bring the Best of Both Worlds to Virtual ISPOR Europe 2020

Join OPEN VIE and Pharmerit – an OPEN Health Company at the ISPOR European Virtual Conference from 16-19 November 2020 to see how we are shaping the healthcare industry with...

OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020

Strategy and execution, data and insight, experience and innovation…what do you look for in an agency partner?OPEN Health is a family of expert practices working in partnership to drive positive...

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward

The COVID-19 pandemic has permanently changed how medical education in the healthcare industry is conducted. Over the last few months, all conferences, medical education and field force deliverables have either...

How Far Do You Want To Go?

Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…

NORD Rare Diseases Breakthrough Summit

Gavin Jones, Director of Rare Disease, provides his thoughts on last week’s NORD Breakthrough Summit and a collective need to reduce inequalities in rare disease